Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Illumina, Inc. stock logo
ILMN
Illumina
$96.45
-1.4%
$98.35
$68.70
$156.66
$15.03B1.41.72 million shs910,931 shs
Moderna, Inc. stock logo
MRNA
Moderna
$27.53
-1.4%
$25.94
$23.15
$59.73
$10.91B2.0112.31 million shs6.84 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Illumina, Inc. stock logo
ILMN
Illumina
+1.14%-4.38%-0.41%-2.27%-29.99%
Moderna, Inc. stock logo
MRNA
Moderna
+2.12%+1.16%+12.44%-18.55%-52.18%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Illumina, Inc. stock logo
ILMN
Illumina
$96.45
-1.4%
$98.35
$68.70
$156.66
$15.03B1.41.72 million shs910,931 shs
Moderna, Inc. stock logo
MRNA
Moderna
$27.53
-1.4%
$25.94
$23.15
$59.73
$10.91B2.0112.31 million shs6.84 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Illumina, Inc. stock logo
ILMN
Illumina
+1.14%-4.38%-0.41%-2.27%-29.99%
Moderna, Inc. stock logo
MRNA
Moderna
+2.12%+1.16%+12.44%-18.55%-52.18%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Illumina, Inc. stock logo
ILMN
Illumina
2.15
Hold$123.5628.10% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.00
Hold$41.8151.88% Upside

Current Analyst Ratings Breakdown

Latest ILMN and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2025
Illumina, Inc. stock logo
ILMN
Illumina
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D+)
10/8/2025
Moderna, Inc. stock logo
MRNA
Moderna
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
10/7/2025
Illumina, Inc. stock logo
ILMN
Illumina
Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$135.00 ➝ $132.00
10/2/2025
Illumina, Inc. stock logo
ILMN
Illumina
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetUnderweight$90.00 ➝ $95.00
9/27/2025
Illumina, Inc. stock logo
ILMN
Illumina
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D+)
9/27/2025
Moderna, Inc. stock logo
MRNA
Moderna
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/2/2025
Illumina, Inc. stock logo
ILMN
Illumina
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$124.00
8/22/2025
Moderna, Inc. stock logo
MRNA
Moderna
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetUnderperform$18.00 ➝ $15.00
8/12/2025
Illumina, Inc. stock logo
ILMN
Illumina
Daiwa America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
8/12/2025
Illumina, Inc. stock logo
ILMN
Illumina
Daiwa Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperformNeutral$94.00
8/4/2025
Illumina, Inc. stock logo
ILMN
Illumina
Stephens
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetOverweight$110.00
(Data available from 10/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Illumina, Inc. stock logo
ILMN
Illumina
$4.37B3.39$4.63 per share20.84$14.96 per share6.45
Moderna, Inc. stock logo
MRNA
Moderna
$3.24B3.32N/AN/A$28.33 per share0.97
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Illumina, Inc. stock logo
ILMN
Illumina
-$1.22B$7.9012.2118.692.3629.36%28.93%10.74%11/3/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$7.53N/AN/AN/A-94.31%-25.96%-20.09%11/6/2025 (Estimated)

Latest ILMN and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2025Q3 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$1.95N/AN/AN/A$893.29 millionN/A
11/3/2025Q3 2025
Illumina, Inc. stock logo
ILMN
Illumina
$1.16N/AN/AN/A$1.07 billionN/A
8/1/2025Q2 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.99-$2.13+$0.86-$2.13$116.26 million$142.00 million
7/31/2025Q2 2025
Illumina, Inc. stock logo
ILMN
Illumina
$1.02$1.19+$0.17$1.50$1.12 billion$1.06 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Illumina, Inc. stock logo
ILMN
Illumina
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Illumina, Inc. stock logo
ILMN
Illumina
0.66
1.81
1.41
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.93
3.77

Institutional Ownership

CompanyInstitutional Ownership
Illumina, Inc. stock logo
ILMN
Illumina
89.42%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
Illumina, Inc. stock logo
ILMN
Illumina
2.60%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Illumina, Inc. stock logo
ILMN
Illumina
9,030153.70 million149.70 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800390.58 million347.62 millionOptionable

Recent News About These Companies

Moderna, Inc. (NASDAQ:MRNA) Given Average Rating of "Hold" by Analysts
Venture financing for mRNA-based vaccines declines 82% in 2025 YTD
Funds dry up for mRNA vaccines amid US political storm
Dave Gammon: mRNA technology is the future of vaccines
Moderna (NASDAQ:MRNA) Shares Up 5.9% - Here's Why

New MarketBeat Followers Over Time

Media Sentiment Over Time

Illumina stock logo

Illumina NASDAQ:ILMN

$96.45 -1.33 (-1.36%)
Closing price 04:00 PM Eastern
Extended Trading
$97.00 +0.55 (+0.57%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Moderna stock logo

Moderna NASDAQ:MRNA

$27.53 -0.39 (-1.40%)
Closing price 04:00 PM Eastern
Extended Trading
$27.56 +0.04 (+0.13%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.